One year on from establishing the baseline on female representation in the U.K. biotech industry, the latest survey shows the “dial is stuck.” Since the first report, representation at the CEO level has crept from 18.3% to 18.7%. That is “a marginal gain that signals a plateau at a time when we need a breakthrough,” said Jane Wall, managing director of the U.K. Bioindustry Association, which compiled the statistics.